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INTRODUCTION {#sec008}
============

Cervical cancer screening programs involving Papanicolaou (Pap) testing, and recently human papillomavirus (HPV) testing, have resulted in a marked decrease in invasive cervical cancer incidence worldwide.\[[@pone.0117525.ref001]\] These screening tests help identify early precancerous changes in the cervix or cervical intraepithelial neoplasia (CIN), which are caused by certain high-risk types of HPV (such as types 16 and 18) and can be removed surgically. Commonly performed procedures include loop excision (large loop excision of the transformation zone (LLETZ) or loop electrosurgical excision (LEEP)), cold knife conization, laser conization, cryotherapy, and laser ablation. These procedures are effective for removing precancerous lesions of the cervix and preventing progression to invasive cervical cancer \[[@pone.0117525.ref002]--[@pone.0117525.ref005]\]; however, they can increase the risk of preterm delivery among women who become pregnant after treatment.\[[@pone.0117525.ref006],[@pone.0117525.ref007]\] Limited research has been done to understand the relationship between these procedures and subsequent fertility.

Surgical procedures on the cervix may contribute to infertility through several possible mechanisms. Cervical stenosis may occur after these procedures, which presents an anatomical barrier to sperm and fertilization.\[[@pone.0117525.ref008]\] Cervical mucus production may decrease after treatment, which could impair sperm motility.\[[@pone.0117525.ref009]\] And, rarely, infection may result from surgery which could lead to obstruction and adhesions within the fallopian tubes.\[[@pone.0117525.ref010]\]

Although each of these mechanisms is plausible, and they may work in concert to lower fertility for women who have had cervical procedures, there is limited research examining the effects of such procedures on fertility. Published studies to date have been limited to case reports, observational studies with small sample sizes, and studies using self-reported data which may be influenced by selective recall bias and misclassification.\[[@pone.0117525.ref006]\]

We examined pregnancy rates in a cohort of women 14--53 years of age at Kaiser Permanente Northwest from 1998 through 2009 to see whether treatments for precancerous cervical lesions were associated with lower pregnancy rates.

MATERIALS AND METHODS {#sec009}
=====================

Retrospective Matched Cohort {#sec010}
----------------------------

Kaiser Permanente Northwest (KPNW) is an integrated health care delivery system serving about 470,000 individuals in northwest Oregon and southwest Washington. We identified all female KPNW members aged 14 to 53 years during the period 1998--2009. We assigned each woman a study start date corresponding to the date upon which she joined the health plan during the 12-year study period, January 1, 1998 for women who were already enrolled at the beginning of the study period, or the date of her 14^th^ birthday. We censored cohort members and assigned them a study end date when they turned 55 years of age, terminated their health plan coverage, or as of December 31, 2009, whichever date occurred first. For women who left and rejoined the health plan during this period, we included all their enrollment periods.

We excluded women who were not "at risk" of becoming pregnant due to a history of hysterectomy, oophorectomy, sterilization, or diagnosed genetic infertility. A list of diagnosis and procedure codes used to define these exclusion criteria is available by request from the authors.

Identification of Exposed Women {#sec011}
-------------------------------

After applying the criteria described above, we identified women who underwent a cervical procedure during the study period using procedure codes. Excisional procedures included loop excision (LEEP or LLETZ) and conization (cold knife, laser, or loop electrode). Ablative procedures included laser ablation, cryosurgery, and cautery (electro or thermal).We assigned each of these women an index date, which was the first date of exposure to any of the qualifying treatment procedures and required her to have been enrolled in the health plan on the index date and for at least six continuous months leading up to the index date. We calculated age at the time of exposure for each woman and stratified the women by year of index date and five-year age categories. These categories were used for frequency matching with the two control groups described below.

Comparison Group Exposed to Cervical Diagnostic Procedures Only {#sec012}
---------------------------------------------------------------

After identifying exposed women, we identified a comparison group of women who were exposed to diagnostic cervical procedures, such as a colposcopy and/or biopsy, during the period 1998--2009 but had not been exposed to cervical treatment procedures. We assigned each woman an index date, which was the first date of exposure to any of the qualifying diagnostic procedures; we required her to have been enrolled in the health plan on the index date and for at least six continuous months leading up to the index date.

Comparison Group Unexposed to Any Cervical Procedures {#sec013}
-----------------------------------------------------

For each woman who met the study inclusion criteria and had not been exposed to any of the diagnostic or treatment cervical procedures of interest during the period 1998--2009, we randomly assigned an index year during which she had been enrolled for at least one month. We calculated age in years for each woman on July 1 of her index year. We then stratified all the women by the assigned index year and five-year age categories.

We frequency-matched unexposed women to women exposed to cervical treatment within index year and five-year age category strata. Within each year-age stratum, we randomly assigned the index dates of the exposed women to the unexposed women as pseudo-index dates. We excluded unexposed women who had not been enrolled in the health plan on their assigned index date and for at least six continuous months leading up to this index date. Our final matching ratio of exposed women to unexposed women was 1:20.

Data Collection {#sec014}
---------------

We collected information about health plan enrollment history, diagnoses, medical procedures, pharmacy dispensings, vital signs, and demographic descriptors from KPNW electronic medical records. The following list of covariates was selected for our analyses: age at index date, race/ethnicity, body mass index (BMI), cigarette smoking status, immunocompromised status, history of sexually transmitted infections (STIs) other than HPV, infertility diagnoses, testing and treatment, contraceptive use, obstetric history, length of prior health plan enrollment, and frequency of health care utilization. We created analytic variables for race, ethnicity and BMI by imputing values for these variables where they were missing. The BMI missing values were first categorized by age group and then assigned the mean BMI value of that specific age group. Most missing values for race/ethnicity were replaced by geo-coded race/ethnicity information from the U.S. 2000 Census. The values that were still missing after utilizing the geo-coded information were replaced by the modal value which was "white".

We collected all available contraceptive use information for the study cohort members from the KPNW pharmacy, procedure, and diagnosis databases, and used this information to create a time-dependent variable representing time exposed and not exposed to a contraceptive method during the study period. We included oral contraceptives, injectable hormonal methods, implantable hormonal methods, and intrauterine devices (IUDs), but did not capture data on emergency contraceptive use, barrier methods, male partner sterilization, or abstinence.

We used a validated algorithm developed by KPNW researchers to identify a woman's first pregnancy after the index date.\[[@pone.0117525.ref011]\] We included pregnancies of all outcome types, not just those ending in live births. The algorithm has good agreement with manual chart review for live births (100%), spontaneous abortions (93%), therapeutic abortions (96%) and stillbirths (88%).

Propensity Score Trimming {#sec015}
-------------------------

We developed propensity scores for the likelihood of exposure to cervical surgical treatment. We computed separate propensity score models for the two comparison groups. All the variables in the propensity score were measured for the time period before the index date. Variables evaluated in propensity score model building included: age, race, ethnicity BMI, cigarette smoking status, immunocompromised status, STI history, obstetric history, diagnosis of infertility, length of prior health plan enrollment, and frequency of health care utilization. We then excluded women from the treatment and two comparison groups whose propensity scores did not overlap with each other.

Analysis {#sec016}
--------

We compared the women exposed to cervical treatment procedures to the women exposed to diagnostic procedures only and to the matched unexposed women using chi square and t-tests as appropriate. We also described contraceptive use and infertility diagnoses, testing, and treatment among the exposed women and two comparison groups during the study period.

We used Cox proportional hazards regression modeling to calculate the rate of pregnancy among exposed women compared to the rates in each of the two comparison groups. Calculation of person-time included days between the index date and the start date of the first pregnancy episode. Person-time was censored as described above at the end of the study period, health plan disenrollment, or a woman's 55^th^ birthday. We plotted the Nelson-Aalen cumulative hazard distribution for all three study groups, and calculated hazard ratios stratified by treatment procedure type (excisional vs. ablative).

We conducted a formal assessment of potential confounders identifying variables that were statistically associated with both pregnancy and treatment and changed the estimate of the treatment effect by 10% or more when included in a bivariate regression model. Contraceptive use was included in the Cox models as a time-dependent covariate. All analyses were conducted using SAS Version 9.2 (SAS Institute, Cary, NC).

Ethics Statement {#sec017}
----------------

The study protocol was reviewed and approved by the Kaiser Permanente Northwest Institutional Review Board (IRB). The study was conducted with a waiver of informed consent issued by the IRB. As part of their membership agreement with KPNW, health plan members sign a statement acknowledging that their medical records information may be used for research purposes; members who opted out of research at the time of health plan enrollment were excluded.

RESULTS {#sec018}
=======

A total of 461,084 female KPNW health plan members 14--53 years of age were identified for the years 1998--2009 ([Fig. 1](#pone.0117525.g001){ref-type="fig"}). Of these, we excluded 638 women who opted out of participation in research studies and 24,789 with a previous hysterectomy or other excluding medical condition, leaving 435,657 potentially-eligible cohort members. After applying study eligibility criteria and propensity score trimming, we identified 4,137 women who received a cervical treatment procedure during the study period (exposed group), and 13,676 women who received a colposcopy and/or biopsy only during the study period (diagnostic procedure comparison group). Applying the 1:20 frequency matching protocol described above, we selected a comparison group of 81,435 women unexposed to either cervical treatment or diagnostic procedures.

![Inclusion and Exclusion Criteria to Establish a Cohort of Women Exposed to Cervical Treatment or Diagnostic Procedures and a Matched Sample of Unexposed Women, Kaiser Permanente Northwest, 1998--2009.](pone.0117525.g001){#pone.0117525.g001}

The treatment and unexposed groups were similar in terms of age due to matching, but the diagnostic procedure group was slightly older than the treatment group ([Table 1](#pone.0117525.t001){ref-type="table"}). Race, ethnicity, and immunocompromised status were consistent across the three groups. Several factors, including infertility, obstetric history, and STI diagnoses, were more common among the treatment group compared to the unexposed group; the distribution of these factors in the diagnostic procedure group was more closely aligned with the treatment group distribution.

10.1371/journal.pone.0117525.t001

###### Characteristics of Women Exposed or Unexposed to Cervical Treatment or Diagnostic Procedures.

![](pone.0117525.t001){#pone.0117525.t001g}

                                                                  Treatment (n = 4,127)   Diagnostic (n = 13,676)   p-value    Unexposed (n = 81,435)   p-value
  --------------------------------------------------------------- ----------------------- ------------------------- ---------- ------------------------ ----------
  Age at Index Date (years)                                       32.15 (9.64)            34.45 (11.36)             \<0.0001   31.53 (9.97)             \<0.0001
  Body Mass Index                                                 26.98 (6.20)            27.22 (6.46)              0.03       27.45 (6.10)             \<0.0001
                                                                  n (%)                   n (%)                                n (%)                    
  Age at Index Date (years)                                                                                                                             
  \<20                                                            286 (7.0)               1,313 (9.6)               \<0.0001   7,448 (9.2)              \<0.0001
  20--29                                                          1,613 (39.0)            4,173 (30.5)                         31,674 (38.9)            
  30--39                                                          1,226 (29.7)            2,863 (20.9)                         23,777 (29.2)            
  ≥40                                                             1,002 (24.3)            5,327 (38.9)                         18,536 (22.8)            
  Race                                                                                                                                                  
  White                                                           3,615 (87.6)            11,738 (85.8)             0.004      71,245 (87.5)            0.84
  Non-White                                                       512 (12.4)              1,938 (14.2)                         10,190 (12.5)            
  Ethnicity                                                                                                                                             
  Hispanic                                                        172 (4.2)               663 (4.9)                 0.07       3,043 (3.7)              0.16
  Non-Hispanic/Unknown                                            3,955 (95.8)            13,013 (95.1)                        78,392 (96.3)            
  Infertility[^a^](#t001fn001){ref-type="table-fn"}                                                                                                     
  Yes                                                             335 (8.1)               1,763 (12.9)              \<0.0001   5,105 (6.3)              \<0.0001
  No                                                              3,792 (91.9)            11,913 (87.1)                        76,330 (93.7)            
  Immunocompromised                                                                                                                                     
  Yes                                                             38 (0.9)                103 (0.8)                 0.29       345 (0.4)                \<0.0001
  No                                                              4,089 (99.1)            13,573 (99.2)                        81,090 (99.6)            
  Prior Obstetric History[^b^](#t001fn002){ref-type="table-fn"}                                                                                         
  Yes                                                             1,121 (27.2)            3,356 (24.5)              0.0007     17,826 (21.9)            \<0.0001
  No                                                              3,006 (72.8)            10,320 (75.5)                        63,609 (78.1)            
  Contraceptive Use                                                                                                                                     
  Yes                                                             2,134 (51.7)            6,175 (45.1)              \<0.0001   25,204 (31.0)            \<0.0001
  No                                                              1,993 (48.3)            7,501 (54.9)                         56,231 (69.0)            
  Sexually Transmitted Infection                                                                                                                        
  Yes                                                             468 (11.3)              1,183 (8.7)               \<0.0001   1,637 (2.0)              \<0.0001
  No                                                              3,659 (88.7)            12,493 (91.3)                        79,798 (98.0)            
  Smoking                                                                                                                                               
  Yes                                                             1,656 (40.1)            4,204 (30.7)              \<0.0001   16,691 (20.5)            \<0.0001
  No                                                              2,471 (59.9)            9,472 (69.3)                         64,744 (79.5)            
  Health Plan Enrollment                                                                                                                                
  \<15 months                                                     833 (20.2)              2,585 (18.9)              \<0.0001   20,694 (25.4)            \<0.0001
  15--36 months                                                   1,161 (28.1)            3,245 (23.7)                         24,267 (29.8)            
  37--72 months                                                   836 (20.3)              2,630 (19.2)                         15,364 (18.9)            
  ≥72 months                                                      1,297 (31.4)            5,216 (38.1)                         21,110 (25.9)            
  Health Care Visits per Year                                                                                                                           
  \<2                                                             197 (4.8)               1,048 (7.7)               \<0.0001   17,414 (21.4)            \<0.0001
  3--4                                                            1,111 (26.9)            4,854 (35.5)                         27,564 (33.8)            
  5--7                                                            1,093 (26.5)            3,323 (24.3)                         15,513 (19.0)            
  ≥8                                                              1,726 (41.8)            4,451 (32.5)                         20,944 (25.7)            

^a^ women with an infertility diagnosis, fertility testing, or fertility treatment

^b^ obstetric history defined as at least one pregnancy documented in the electronic medical record prior to the index date

Smoking was more common among the treatment group (40%) compared to the unexposed group (21%) and the diagnostic procedure group (31%). Length of prior enrollment and mean number of medical visits per year were modestly higher in the treatment group compared to the unexposed; however, the diagnostic procedure group had the largest proportion of women with \>36 months prior membership in the health plan (57% diagnostic vs. 52% treatment vs. 45% unexposed).

Fifty-two percent of the treatment group used contraceptives at some time during the study period, compared to 31% of the unexposed group (p\<.0001) and 45% of the diagnostic procedure group (p\<.0001). In all groups, oral contraceptives were the most commonly-used method, followed by injectables, IUDs, and implants (data not shown).

We observed 570 pregnancies (14%) following surgical treatment (index date) in exposed women, 7,436 pregnancies (9%) in unexposed women after their index date, and 1,533 pregnancies (11%) following colposcopy/biopsy in the diagnostic procedure group. Compared to unexposed women, pregnancies were more common in the treatment group (hazard ratio (HR) = 1.35, 95% confidence interval (CI): 1.24--1.47) ([Table 2](#pone.0117525.t002){ref-type="table"}). Similarly, the rate of pregnancies in the treatment group was higher than the rate in the diagnostic procedure comparison group (HR = 1.35, 95% CI: 1.22--1.48). Age and contraceptive use emerged as important confounders in both comparison groups in these models; pregnancy rates decreased with increasing age and during periods of contraceptive use. Infertility was also a confounder in the treatment vs. unexposed models. After adjusting for these confounders, we continued to observe a higher rate of pregnancies in the treatment group compared to unexposed women (HR = 1.42, 95% CI: 1.30--1.55), but there was no difference in pregnancy rates between the treatment group and the diagnostic procedure group (HR = 1.03, 95% CI: 0.93--1.13).

10.1371/journal.pone.0117525.t002

###### Pregnancy among Women Exposed or Unexposed to Cervical Treatment orDiagnostic Procedures.

![](pone.0117525.t002){#pone.0117525.t002g}

                                       Crude HR (95% CI)   Adjusted [^a^](#t002fn003){ref-type="table-fn"} HR (95% CI)
  ------------------------------------ ------------------- -------------------------------------------------------------
  Contraceptive Use (time-dependent)                       0.24 (0.22--0.28)
  Age at Index Date                                        
  \<20 years                                               1.0 (ref)
  20--29 years                                             0.88 (0.79--0.99)
  30--39 years                                             0.31 (0.28--0.36)
  40+ years                                                0.01 (0.01--0.01)

HR = hazard ratio;

CI = confidence interval

^a^ adjusted for all covariates listed

Figs. [2](#pone.0117525.g002){ref-type="fig"} and [3](#pone.0117525.g003){ref-type="fig"} show Nelson-Aalen plots of the cumulative hazard in all three study groups. Across all years of follow up, women in the treatment group were more likely to become pregnant than women in either of the two comparison groups.

![Time to Pregnancy among Women Exposed or Unexposed to Cervical Treatment Procedures over 12 Years of Follow-Up.](pone.0117525.g002){#pone.0117525.g002}

![Time to Pregnancy among Women Exposed to Cervical Treatment Procedures or Diagnostic Procedures over 12 Years of Follow-Up.](pone.0117525.g003){#pone.0117525.g003}

Nine hundred seventy-six women were exposed to ablative treatment procedures and 3,151 were exposed to excisional procedures. We observed similar adjusted hazard ratios for ablative procedures (HR = 1.40, 95% CI: 1.21--1.63) compared to excisional procedures (HR = 1.42, 95% CI: 1.29--1.58) using the unexposed comparison group. Similarly, there was little difference in adjusted hazard ratios for ablative (HR = 0.95, 95% CI: 0.81--1.11) and excisional procedures (HR = 1.07, 95% CI: 0.95--1.19) compared to women exposed to diagnostic procedures.

DISCUSSION {#sec019}
==========

In a cohort of over 435,000 women with up to 12 years of follow-up time, we did not observe any adverse effects of cervical treatment procedures on subsequent pregnancy rates. In fact, we observed increased pregnancy rates in women who underwent these procedures compared to unexposed women and women who received diagnostic procedures only. Several characteristics we measured suggest that the women in the treatment group may have been more sexually active than women in the comparison groups, but one major limitation of this study is that we were not able to assess sexual activity directly nor were we able to evaluate intention to become pregnant.

There are few published studies on this topic with which to compare our findings.\[[@pone.0117525.ref006]\] Four previous studies with control groups reported on total number of pregnancies, ability to conceive within a specified period, and time to pregnancy.\[[@pone.0117525.ref012]--[@pone.0117525.ref015]\] None of these studies suggest an adverse effect of cervical procedures on these outcomes. Consistent with our findings, one study found an increased probability of pregnancy in the treatment group compared to a matched unexposed group.\[[@pone.0117525.ref014]\] These prior studies were very heterogeneous in design, included small sample sizes, and may have been influenced by selection bias and misclassification because they primarily relied on survey data and fertility clinic records. Our study overcomes some of these limitations by examining a large, population-based cohort with outcomes and exposures derived from electronic medical records data rather than self-report. An additional strength of our study is that we were able to capture data on a number of important covariates, including contraceptive use, from our comprehensive databases.

Our findings that certain characteristics and behaviors, such as smoking and STI diagnoses, are more common among women exposed to these procedures is consistent with many other published studies.\[[@pone.0117525.ref012],[@pone.0117525.ref016]\] To better control for these unbalanced covariates, we included a comparison group of women who underwent diagnostic procedures thinking that these women would also have been exposed to HPV and likely had sexual behaviors and exposures more similar to the treatment procedures group. This diagnostic procedure comparison group did indeed more closely resemble the exposed group, but there are likely still some unmeasured confounders we were unable to capture and control for in our analyses. As noted above, we were not able to directly ascertain sexual activity and intention to conceive, nor were we able to capture data on barrier contraceptive methods or abstinence.

While we believe our finding of increased pregnancy rates among women undergoing cervical treatments most likely represents unmeasured confounding, there may be an underlying biologic relationship between pregnancy and progression of HPV infection to precancerous lesions and cervical cancer. Several studies have reported that multiparity is associated with an increased risk of cervical intraepithelial neoplasia, and several authors have speculated that hormonal and immunologic changes during pregnancy may facilitate HPV DNA integration and progression of infection.\[[@pone.0117525.ref017],[@pone.0117525.ref018]\] Alternatively, there may be factors (such as host immune responses) that both make successful pregnancy more likely and facilitate HPV integration and progression. Women undergoing cervical treatment or diagnostic procedures in our study were more likely to have been pregnant prior to their index date than unexposed women, but obstetric history did not emerge as an important confounder in our analysis. Additional research is needed to better understand possible underlying pathways between HPV infection, progression, and fertility.

Cervical cancer screening and early detection and surgical treatment of precancerous lesions have led to a decrease in cervical cancer incidence. Use of HPV vaccines should also lead to further declines in cervical cancer incidence in the future. We found no evidence to suggest that cervical treatments have a negative effect on the ability to become pregnant in the early years following treatment and in up to twelve years following treatment; however, these procedures have been associated with an increased risk of pregnancy outcomes such as preterm delivery.\[[@pone.0117525.ref006],[@pone.0117525.ref007]\] Although there are still gaps in our understanding of how these treatments may influence fertility, these results should be reassuring to clinicians and to women undergoing these procedures during their childbearing years.
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